Pharmaceuticals company Ipca Laboratories announced Q3FY25 results Standalone Net total Income up 10% at Rs 1,680.09 crore. Consolidated Net total Income up 9% at Rs 2,265.48 crore. Indian formulations income up 13% at Rs 877.17crore. Exports Income up 6% at Rs 680.91 crore. Standalone EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 24.25% in Q3FY25 as against @ 18.52% in Q3FY24. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 19.87% in Q3FY25 as against @ 16.10% in Q3FY24. Standalone Net Profit at Rs 267.56 crore (after exceptional items) up 95%. Consolidated Net Profit at Rs 248.14 crore (after exceptional items) up 38%. Result PDF